|
Vol 54(2020) N 5 p. 639-660; DOI 10.1134/S0026893320050118 ![]() V.M. Ushakova1,2*, A.Yu. Morozova1,4, A.M. Reznik3, G.P. Kostyuk4, V.P. Chekhonin1,5 Molecular Biological Aspects of Depressive Disorders: A Modern View 1Serbsky National Medical Research Center of Psychiatry and Narcology, Moscow, 119034 Russia2Moscow State University, Moscow, 119234 Russia 3Moscow State University of Food Production, Moscow, 125080 Russia 4Alekseev Psychiatric Clinical Hospital no. 1, Moscow, 117152 Russia 5Pirogov Russian National Research Medical University, Moscow, 117997 Russia *ushakovavm@yandex.ru Received - 2020-04-21; Revised - 2020-05-15; Accepted - 2020-05-16 Depression is a serious mental disorder that affects more than 300 million people worldwide. Due to the lack of effective treatment methods, the pathogenesis of depression is necessary to study in order to understand its development and find new therapies. The review describes the main mechanisms of depression, including the monoamine hypothesis, impairment of the hipotalamic-pituitary-adrenal axis, decreased production of neurotropic factors, and neuroinflammation. Genetic correlations, gene polymorphisms, and epigenetic mechanisms are also considered. Common and different features of the etiology are analyzed for depression and depressive conditions associated with other pathologies (schizophrenia, Parkinson disease, and Alzheimer's disease). Modern experimental methods used to investigate the molecular mechanisms of depressive conditions are described with a focus on gene knockouts in laboratory animals and the CRISPR/Cas technology. Consideration is given to optogenetic and chemogenetic methods and analyses of genetic polymorphisms and their combinations. The data may provide for a better integral understanding of the modern ideas about the pathogenesis of depression as an isolated or comorbid disorder and the prospects in studying the mechanisms of depressive conditions. depression pathogenesis, schizophrenia, bipolar disorder, neurodegeneration, monoamines, BDNF, neuroinflammation, epigenetics, CRISPR/Cas, optogenetics |